Category: 33821-94-2

The reaction rate of a catalyzed reaction is faster than the reaction rate of the uncatalyzed reaction at the same temperature.33821-94-2, Name is 2-(3-Bromopropoxy)tetrahydro-2H-pyran, molecular formula is C8H15BrO2. In a Article£¬once mentioned of 33821-94-2, name: 2-(3-Bromopropoxy)tetrahydro-2H-pyran

Palladium-catalyzed arylation of ketone enolates: an expeditious entry to tamoxifen-related 1,2,2-triarylethanones.

[reaction: see text]. After a rigorous study on the effect of several catalytic systems, a simple, high yielding procedure for the preparation of 1,2,2-triarylethanones, skeletal analogues of tamoxifen, is presented. Apart from the economic and environmental advantages involved, this palladium-catalyzed arylation of deoxybenzoin enolates features a lack of ortho-arylation side reactions. In addition, an alternative approach from acetophenones to the target triarylethanone system is also announced.

Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.name: 2-(3-Bromopropoxy)tetrahydro-2H-pyran, you can also check out more blogs about33821-94-2

Reference£º
Tetrahydropyran – Wikipedia,
Tetrahydropyran – an overview | ScienceDirect Topics

33821-94-2, In an article, published in an article,authors is Bhatt, Suchitra, once mentioned the application of 33821-94-2, Name is 2-(3-Bromopropoxy)tetrahydro-2H-pyran,molecular formula is C8H15BrO2, is a conventional compound. this article was the specific content is as follows.

Copper(II) bromide: A simple and selective monobromination reagent for electron-rich aromatic compounds

Copper(II) bromide was found to be a simple and efficient reagent for monobromination of electron-rich aromatic compounds at room temperature. The reaction proceeded smoothly with phenols, aryl alkyl ethers, and aromatic amines to afford the corresponding monobrominated product selectively in moderate to good yields. Copyright Taylor & Francis Group, LLC.

If you are interested in 33821-94-2, you can contact me at any time and look forward to more communication.33821-94-2

Reference£º
Tetrahydropyran – Wikipedia,
Tetrahydropyran – an overview | ScienceDirect Topics

33821-94-2, 2-(3-Bromopropoxy)tetrahydro-2H-pyran is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a solution of 2-bromo-3-hydroxybenzaldehyde (5.18 g, 25.0 mmol) and 2-(3-bromopropoxy)tetrahydro-2H-pyran (5.1 mL, 30 mmol) in DMF (60 mL) was added sodium hydride (1.20 g, 30.0 mmol) at O0C under nitrogen atmosphere, and the mixture was stirred at room temperature for overnight. The reaction was quenched with water, and the mixture was extracted with ethyl acetate. The organic layer was washed with water twice and brine, and dried on anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the residue was purified by silica gel column chromatography (9:1 to 3:1 hexane/ethyl acetate) to give 2-bromo-3-[3- (tetrahydropyran-2-yloxy)propoxy]benzaldehyde (8.75 g, quantitative)., 33821-94-2

33821-94-2 2-(3-Bromopropoxy)tetrahydro-2H-pyran 2777988, aTetrahydropyrans compound, is more and more widely used in various fields.

Reference£º
Patent; ANACOR PHARMACEUTICALS, INC.; WO2008/157726; (2008); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

33821-94-2, 2-(3-Bromopropoxy)tetrahydro-2H-pyran is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Intermediate Compound 2 Compound 2 (8.2 g, 31.9 MMOL) was dissolved in THF (200 mL) and cooled TO-78C. LHMDS (1 M in THF, 33.5 MMOL) was added and the content stirred AT-78C for 10 min before being transferred to a solution of 2- (3- bromopropoxy) -tetrahydro-2H-pyran (6.48 mL, 38.29 MMOL) at r. t via canula. The reaction was completed in 4 hrs and solvents were removed under reduced pressure, residue redissolved in ethyl acetate and washed with 1: 1 brine: H20, dried, filtrated and concentrated. FCC with hexane: EtOAc (5: 1 to 4: 1) afford 7.4 g of the intermediate product 3 as light yellow oil., 33821-94-2

As the paragraph descriping shows that 33821-94-2 is playing an increasingly important role.

Reference£º
Patent; SMITHKLINE BEECHAM CORPORATION; WO2004/55016; (2004); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.33821-94-2,2-(3-Bromopropoxy)tetrahydro-2H-pyran,as a common compound, the synthetic route is as follows.

Step-(i): To a stirred solution of 140a (1.2 g, 2.93 mmol) in DMF (10 ml) were added triethylamine (1.3 ml, 8.79 mmol), 2-(3-brortiopropoxy)tetrahydro-2H-pyran (0.91 g, 3.50 mmol) at 0C and the reaction mixture was stirred at 20-35C for 16 h. The progress of the reaction was monitored by TLC. After 16 h of stirring, the reaction mixture was diluted with water (50 ml) and extracted with dichloromethane (2 x 50 ml). The combined organic layers were washed with brine (50 ml), followed by drying over anhydrous Na2S04 and filtering. The filtrate was rotary evaporated to get residue which was purified by column chromatography using a mixture of 2% methanol/dichloromethane as an eluent to get the desired compound as an off-white solid (1.05 g, 82%). ]H NMR (400 MHz, DMSO-d6) delta 10.63 (s, I H), 8.21 (d, J = 1.9 Hz, IH), 7.90 (d, J = 2.0 Hz, IH), 4.53 (d, J = 3.9 Hz, IH), 3.77-3.69 (m, IH), 3.68-3.54 (m, 2H), 3.49-3.32 (m, 3H), 2.91 (s, 2H), 2.63-2.52 (m, 2H), 2.36-2.32 (m, 2H), 2.26-2.22 (m, 2H), 1.82 (t, J = 9.8 Hz, 2H), 1.77-1.57 (m, 4H), 1.52-1.40 (m, 3H), 1.38-1.26 (m, IH).

33821-94-2, 33821-94-2 2-(3-Bromopropoxy)tetrahydro-2H-pyran 2777988, aTetrahydropyrans compound, is more and more widely used in various fields.

Reference£º
Patent; AURIGENE DISCOVERY TECHNOLOGIES LIMITED; TAKHI, Mohamed; HOSAHALLI, Subramanya; PANIGRAHI, Sunil Kumar; MAHADARI, Muni Kumar; KOTTAM, Chandrashekar Reddy; ABD RAHMAN, Noorsaadah; YUSOF, Rohana; WO2013/80222; (2013); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.33821-94-2,2-(3-Bromopropoxy)tetrahydro-2H-pyran,as a common compound, the synthetic route is as follows.

Intermediate 26: 2-[3-(2,4-difluorophenyl)sulfanylpropoxy]oxane Sodium hydride (60%) (1.72 g, 44.8 mmol) was added to a solution of 2,4-difluorobenzenethiol (CAS no. 1996-44-7) (4.6 mL, 40 mmol) in THF (150 mL) at 0 C., under argon. The mixture was allowed to warm to room temperature and 2-(3-bromopropoxy)oxane (CAS no. 33821-94-2) (7.6 mL, 45 mmol) was added. The reaction was stirred at ambient temperature for 16 hours. The mixture was poured into ice/water (250 mL) and extracted with ethyl acetate (250 mL). The organic extract was washed with brine, dried (MgSO4) and the solvent removed under reduced pressure. The residue was purified by flash chromatography, eluding with 0-10% ethyl acetate in isohexane afford the product (10.8 g, 84%). 1H NMR 6 (400 MHZ, CDCl3): 1.49-1.61 (m, 4H), 1.65-1.73 (m, 1H), 1.75-1.90 (m, 3H), 2.96 (t, 2H), 3.46-3.52 (m, 2H), 3.79-3.87 (m, 2H), 4.55-4.56 (m, 1H), 6.80-6.86 (m, 2H), 7.38-7.44 (m, 1H)., 33821-94-2

33821-94-2 2-(3-Bromopropoxy)tetrahydro-2H-pyran 2777988, aTetrahydropyrans compound, is more and more widely used in various fields.

Reference£º
Patent; AstraZeneca AB; US2008/171734; (2008); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

33821-94-2, 2-(3-Bromopropoxy)tetrahydro-2H-pyran is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,33821-94-2

Following a similar procedure, 27 was synthesized from 1,3-benzenediol and 2-(3-bromopropoxy)tetrahydropyran.35 Clear oil.Yield 72%. IR (KBr, cm1) 1183, 1155, 1140, 1124, 1077, 1035(tetrahydropyranyl ring). 1H NMR (CDCl3) d: 7.18-7.11 (m, 1H),6.53-6.46 (m, 3H), 4.63-4.57 (m, 2H), 4.12-4.02 (m, 4H), 3.96-3.80 (m, 4H), 3.61-3.45 (m, 4H), 2.07 (quintet, 4H, J = 6.5 Hz),1.88-1.46 (m, 4H). 13C NMR (CDCl3) d: 160.25, 129.76, 106.78,101.55, 98.94, 64.92, 64.03, 62.30, 30.70, 29.70, 25.47, 19.59.C22H34O6 requires: C 66.98; H 8.69. Found: C 66.96; H 8.89.

33821-94-2 2-(3-Bromopropoxy)tetrahydro-2H-pyran 2777988, aTetrahydropyrans compound, is more and more widely used in various fields.

Reference£º
Article; Lucchesini, Francesco; Pocci, Marco; Alfei, Silvana; Bertini, Vincenzo; Buffoni, Franca; Bioorganic and Medicinal Chemistry; vol. 22; 5; (2014); p. 1558 – 1567;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.33821-94-2,2-(3-Bromopropoxy)tetrahydro-2H-pyran,as a common compound, the synthetic route is as follows.

Step 2: 4-(2-chloro-8-iodo-9-(3-(tetrahydro-2H-pyran-2-yloxy)propyl)-9H-purin- 6-yl)morpholineTo a suspension of 4-(2-chloro-8-iodo-9-(tetrahydro-2H-pyran-2-yl)-9H-purin-6- yl)morpholine (0.655 g, 1.46 mmol) in methanol (6 mL) was added a catalytic amount of p- toluenesulfonic acid (25 mg, 0.14 mmol). The reaction mixture was heated at 50 C for an overnight period. After this time, the mixture was cooled to room temperature and the volume of methanol was reduced by vacuum evaporation. The resulting residue was diluted with sat.aqueous NaHC03 solution. The precipitate that formed was collected by filtration. In total, 295 mg (56%) of 4-(2-chloro-8-iodo-9H-purin-6-yl)morpholine was obtained as a white solid which was dissolved in anhydrous DMF (2.5 mL). Cesium carbonate (0.53 g, 1.61 mmol) was added and the mixture was stirred together 10 min at 23 C. Subsequently l-(2H-3,4,5,6- tetrahydropyran-2-yloxy)-3-bromopropane (0.54 g, 2.42 mmol) was introduced to the mixture. The resulting reaction mixture was heated at 50 C for 2 h. Complete conversion was observed at the end of this period. The reaction was worked up by dilution with 1 N HCl and EtOAc. The phases were separated and the aqueous layer was extracted twice with EtOAc. The combined organic portions were dried over MgS04, filtered and concentrated in vacuo. The residue was purified by FCC (40 g silica gel column, 0-50% EtOAc in heptane) to give 385 mg (94% yield) of 4-(2-chloro-8-iodo-9-(3-(tetrahydro-2H-pyran-2-yloxy)propyl)-9H-purin-6-yl)morpholine as a pale yellow solid. MS (ESI+): m/z 508.0 (M+H+), 33821-94-2

The synthetic route of 33821-94-2 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; F. HOFFMANN-LA-ROCHE AG; DOTSON, Jennafer; HEALD, Robert Andrew; HEFFRON, Timothy; JONES, Graham Elgin; KRINTEL, Sussie Lerche; MCLEAN, Neville James; NDUBAKU, Chudi; OLIVERO, Alan G.; SALPHATI, Laurent; WANG, Lan; WEI, BinQing; WO2012/82997; (2012); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

33821-94-2, 2-(3-Bromopropoxy)tetrahydro-2H-pyran is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Scheme 16. Preparation of rifabutin bisphosphonate conjugates 89.; [00282] Tetraethyl 4-(2-Tetrahydro-2H-pyranyloxy)butylene-1,1-bisphosphonate (80): To a suspension of NaH (60% suspension in mineral oil, 900 mg, 22.0 mmol) in dry THF (20 ml.) was added dropwise tetraethyl methylenebisphosphonate (6.46 g, 22.4 mmol). The resulting clear solution was stirred 15 min at room temperature, after which 2-(3- bromopropoxy)tetrahydro-2H-pyran (5.05 g, 22.6 mmol) was added dropwise. The reaction mixture was heated to reflux for 6 h, diluted with CH2CI2 (75 ml.) and washed with brine (2 x 50 ml_), dried (MgSO4) and evaporated. It was used as such in the following step.

33821-94-2, As the paragraph descriping shows that 33821-94-2 is playing an increasingly important role.

Reference£º
Patent; DIETRICH, Evelyne; REDDY, Ranga; TANAKA, Kelly; KANG, Ting; LAFONTAINE, Yanick; RAFAI FAR, Adel; TARGANTA THERAPEUTICS CORP.; WO2010/19511; (2010); A2;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.33821-94-2,2-(3-Bromopropoxy)tetrahydro-2H-pyran,as a common compound, the synthetic route is as follows.

To a solution of ethyl 1 -(6-(2-(4-hydroxy-2-methylphenethyl) phenyl)pyridin-2-yl)-5- (trifluoromethyl)-1 H-pyrazole-4-carboxylate (600 mg, 1.211 mmol, preparation described in Example 1) in acetone (15 ml) was added Cs2003 (592 mg, 1.816 mmol). After stirring for 30 mi 2-(3-bromopropoxy)tetrahydro-2H-pyran (324 mg, 1.453 mmol) was added andthe reaction was heated overnight at 65C. Analysis of the reaction by TLC showed the reaction was complete. The reaction mixture was concentrated in vacuo, diluted with DCM and washed with H20. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The product was purified by chromatography on a Isco Companion. The sample was loaded on 10 g Biotage silica (Si) column then the purification was carried out using a Cyclohexane / EtOAc 100/0 to 80/20. The appropriatefractions were combined and concentrated in vacuo to give the required product as a colorless oil (710 mg, 92%). LC/MS rt = 4.62 mm m/z = 554 [M+H]-THP., 33821-94-2

As the paragraph descriping shows that 33821-94-2 is playing an increasingly important role.

Reference£º
Patent; GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED; GOODMAN, Krista B.; KRAUSS, Achim Hans-Peter; LE MONNIER DE GOUVILLE, Anne-Charlotte; DODIC, Nerina; WO2015/33307; (2015); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics